TANDEM DIABETES CARE INC Fair Value Disclosure
Fair Value Measurements at December 31, 2024 | |||||||||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets | |||||||||||||||||||||||
Cash equivalents(1) | $ | 56,234 | $ | 56,234 | $ | — | $ | — | |||||||||||||||
| United States Government-sponsored enterprises | 133,280 | — | 133,280 | — | |||||||||||||||||||
| United States Treasury securities | 103,702 | 103,702 | — | — | |||||||||||||||||||
| Commercial paper | 23,264 | — | 23,264 | — | |||||||||||||||||||
| Corporate debt securities | 105,836 | — | 105,836 | — | |||||||||||||||||||
Foreign government bonds | 3,013 | — | 3,013 | — | |||||||||||||||||||
| Total assets | $ | 425,329 | $ | 159,936 | $ | 265,393 | $ | — | |||||||||||||||
Fair Value Measurements at December 31, 2023 | |||||||||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets | |||||||||||||||||||||||
Cash equivalents(1) | $ | 48,033 | $ | 48,033 | $ | — | $ | — | |||||||||||||||
| United States Government-sponsored enterprises | 182,154 | — | 182,154 | — | |||||||||||||||||||
| United States Treasury securities | 115,004 | 115,004 | — | — | |||||||||||||||||||
| Commercial paper | 72,511 | — | 72,511 | — | |||||||||||||||||||
| Corporate debt securities | 39,375 | — | 39,375 | — | |||||||||||||||||||
| Total assets | $ | 457,077 | $ | 163,037 | $ | 294,040 | $ | — | |||||||||||||||
Fair Value Measurements at | |||||||||||
| December 31, 2024 | December 31, 2023 | ||||||||||
Convertible Senior Notes due 2025 | $ | 39,130 | $ | 271,688 | |||||||
Convertible Senior Notes due 2029 | 407,752 | * | |||||||||
Total fair value of outstanding convertible senior notes | $ | 446,882 | $ | 271,688 | |||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Feb 26, 2025 | Showing above |
| 2023 | Feb 21, 2024 | |
| 2022 | Feb 22, 2023 | |
| 2020 | Feb 24, 2021 | |
| 2018 | Feb 26, 2019 | |
| 2017 | Mar 1, 2018 | |
| 2016 | Mar 8, 2017 | |
| 2015 | Feb 24, 2016 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.